Description
Key facts
Cell type:THP-1,
Species or organism:Human,
Tissue:Blood,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 61 bp deletion in exon 1,
Disease:Acute Monocytic Leukemia
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
Treatments:
Human CCL3 knockout THP-1 cell lysate - Brefeldin A (5 μg/ml, 6h)
Human wild-type THP-1 cell lysate - Brefeldin A (5 μg/ml, 6h)
Human CCL3 knockout THP-1 cell lysate - PMA (100 ng/ml, 56h), LPS (1 μg/ml, 24h) and Brefeldin A (5 μg/ml, during the last 6hr of LPS treatment)
Human wild-type THP-1 cell lysate - PMA (56h, 100 ng/ml), LPS (24h, 1 μg/ml) and Brefeldin A (5 μg/ml, during the last 6hr of LPS treatment)
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
Properties and Storage Information:
Gene name-CCL3, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MIP-1 alpha also known as CCL3 is a chemokine that plays a critical role in the immune system. With a molecular weight of around 8 kDa it is primarily expressed in activated T-cells macrophages and fibroblasts. MIP-1 alpha acts as a signaling protein that binds to receptors on target cells directing the movement of immune cells. Researchers commonly refer to it using various alternative names such as MIP-1a and CCL3-alpha rat and it is frequently measured using assays like MIP-1 alpha ELISA for experimental analyses.
Biological function summary
Proteins including MIP-1 alpha participate in the recruitment and activation of diverse immune cells aiding the inflammatory response. Through interaction with receptors like CCR1 and CCR5 MIP-1 alpha mobilizes cells like natural killer cells and monocytes. This chemokine does not generally form part of a larger protein complex but interacts directly with membrane receptors to exert its function in immune cell chemotaxis.
Pathways
MIP-1 alpha operates in the context of both the inflammatory response and the chemokine signaling pathways. Its involvement in these pathways helps mediate the trafficking of leukocytes. Notably MIP-1 alpha interacts with proteins such as CCR1 and CCR5 to transmit signals that instigate immune responses. These proteins are integral to its role in modulating immunity providing targets for research into controlling inflammatory processes.
MIP-1 alpha closely relates to conditions such as rheumatoid arthritis and HIV infection. In rheumatoid arthritis its overexpression can lead to excessive inflammation and joint destruction. Meanwhile in HIV infection MIP-1 alpha interacts with CCR5 a co-receptor necessary for the virus entry into cells. This dual relationship elucidates its potential as a therapeutic target in managing both inflammatory diseases and viral entry mechanisms.
